- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01524029
Digital Breast Tomosynthesis Versus Digital Mammography: A National Multicenter Trial
Digital Breast Tomosynthesis vs. Digital Mammography: A National Multicenter Trial
The goal of this study is to determine the value of the new mammography technique called Digital Breast Tomosynthesis (DBT) compared to the current standard technique Digital Mammography for the early detection of Breast Cancer.
DBT is able to compute a three-dimensional image of a breast from several low-dose mammographies taken from different angles while the device is moving around the breast in a circular motion. This should overcome a significant limitation of Digital Mammography arising from the masking of breast cancer in a mammography image caused by overlying normal breast tissue.
This is a study conducted in several Austrian Breast Imaging Centers.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This prospective national multicenter multivendor trial aims at determining the impact of the novel technique Digital Breast Tomosynthesis (DBT) in the assessment and screening for breast cancer. Mammography is the primary imaging modality for the early detection of clinically occult breast cancer.
Despite advances in mammographic technique, mammography is still limited with regard to both sensitivity and specificity. In the majority of cases these limitations arise from the masking of subtle breast cancer lesions by overlapping breast tissue.
DBT is a novel technique that tries to overcome these limitations by performing a 3D-reconstruction of breast tissue from multiple low-dose digital mammographic images acquired in several planes in a 15 to 50 degree angle.
Early studies indicate an advantage of DBT compared to the standard Full Field Digital Mammography (FFDM) in terms of an improvement of specificity without cutback in sensitivity.
Controversy continues over the use of DBT in combination with FFDM or as a standalone screening method without concomitant 2D imaging. Unfortunately, the peer-reviewed publications evaluating DBT are limited and consist of single institution studies with a small number of participants.
The purpose of this study is to evaluate the novel technique of DBT compared to routine FFDM in a clinical large sample study (600 participants) to provide the path to implementation of this new technique into clinical and screening routine.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
-
Vienna, L'Autriche, A-1090
- Recrutement
- Medical University of Vienna
-
Contact:
- Thomas Moritz, MD
- Numéro de téléphone: 4818 +43140400
- E-mail: thomas.moritz@meduniwien.ac.at
-
Vienna, L'Autriche, A-1100
- Recrutement
- Kaiser Franz Josef Spital
-
Contact:
- Gabrielle Kienzer, MD
- Numéro de téléphone: 3608 +43160191
- E-mail: Gabrielle.kienzer@wienkav.at
-
Vienna, L'Autriche, A-1140
- Recrutement
- Hanusch Krankenhaus
-
Contact:
- Reinhard Bernt, MD
- Numéro de téléphone: 86630 +43191021
- E-mail: reinhard.bernt@wgkk.at
-
-
Styria
-
Graz, Styria, L'Autriche, A-8036
- Recrutement
- Medical University of Graz
-
Contact:
- Sabine Oswald, MD
- Numéro de téléphone: 13850 +43 316385
- E-mail: sabine.oswald@klinikum-graz.at
-
-
Upper Austria
-
Wels, Upper Austria, L'Autriche, A-4600
- Recrutement
- Klinikum Wels-Grieskirchen
-
Contact:
- Stefan Meindl, MD
- Numéro de téléphone: 2413 +437242415
- E-mail: stefan.meindl@klinikum-wegr.at
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study population consists of two groups:
One screening group consisting of asymptomatic women (Age 40+) referred for a screening mammography examination.
The second group consists of women aged 25+ referred for further examination of a breast lesion.
La description
Inclusion Criteria:
- Age > 25 years (40 years or older for Screening Cohort)
- No history of breast cancer
- Written informed consent
- Asymptomatic women in follow up for early detection of breast cancer or
- Patients with a recent positive mammography (BI-RADS 3-5)
Exclusion Criteria:
- Pregnant and breast feeding women
- Unable to tolerate breast compression
- Breast implants
- Unable to understand or execute written informed consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Breast Cancer Screening Patients
Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
|
Diagnostic Patients
Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Specificity of Digital Breast Tomosynthesis in the characterization of Breast lesions
Délai: One year
|
One year
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Sensitivity of Digital Breast Tomosynthesis in the detection of malignant breast lesions
Délai: One year
|
One year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Thomas Moritz, MD, Medical University of Vienna
- Directeur d'études: Thomas Helbich, MD Prof. MBA MSc, Medical University of Vienna
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TomoTrial001
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeurs mammaires
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie